Back to top

Analyst Blog

Merck & Co. Inc. (MRK - Analyst Report) is scheduled to report fourth quarter 2013 results before the opening bell on Feb 5. Last quarter, Merck had posted an earnings surprise of +4.55%. Let’s see how things are shaping up for this announcement.

Factors at Play

In addition to facing generic competition for several products, Merck’s top-line will remain under pressure with Januvia’s performance lagging expectations. Although Merck is working on reviving sales, we remain concerned about the rebate and pricing pressure being faced by Januvia due to the entry of new products in the diabetes market.

Meanwhile, the performance of the vaccine segment and the cost-cutting efforts should partially offset the impact of genericization.

Earnings Whispers?

Our proven model does not conclusively show that Merck is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP (Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for this to happen. That is not the case here as you will see below.

Zacks ESP: The Earnings ESP for Merck is -1.12% since the Most Accurate estimate is $0.88 while the Zacks Consensus Estimate is $0.89.

Zacks #3 Rank (Hold): Merck’s Zacks Rank #3 (Hold) has little effect on the predictive power of ESP because the Zacks Rank #3 when combined with a negative ESP makes surprise prediction difficult.

Other Stocks to Consider

Here are some other companies you may want to consider as our model shows that they have the right combination of elements, i.e., a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3.

Actavis plc (ACT - Analyst Report) has an Earnings ESP of +0.66% and holds a Zacks Rank #1 (Strong Buy). Actavis will be reporting fourth quarter earnings on Feb 20.

Sanofi (SNY - Analyst Report) has earnings ESP of +2.27% and holds a Zacks Rank #3. Sanofi will report fourth quarter earnings on Feb 6.

Allergan Inc. (AGN - Analyst Report) has earnings ESP of +0.75% and holds a Zacks Rank #2 (Buy). Allergan will report fourth quarter earnings on Feb 5.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LITHIA MOTO… LAD 94.59 +4.60%
DELTA AIR L… DAL 39.15 +3.90%
FLAMEL TECH… FLML 14.51 +3.50%
SOUTHWEST A… LUV 28.87 +2.92%
NUSTAR GP H… NSH 41.14 +2.59%